1. Red blood cell transfusion and mortality after transcatheter aortic valve implantation via transapical approach: A propensity-matched comparison from the TRITAVI registry
- Author
-
Francesco Radico, Fausto Biancari, Fabrizio D’Ascenzo, Francesco Saia, Giampaolo Luzi, Francesco Bedogni, Ignacio J. Amat-Santos, Vincenzo De Marzo, Arnaldo Dimagli, Timo Mäkikallio, Eugenio Stabile, Sara Blasco-Turrión, Luca Testa, Marco Barbanti, Corrado Tamburino, Italo Porto, Franco Fabiocchi, Federico Conrotto, Francesco Pelliccia, Giuliano Costa, Giulio G. Stefanini, Andrea Macchione, Michele La Torre, Francesco Bendandi, Tatu Juvonen, Vincenzo Pasceri, Wojciech Wańha, Umberto Benedetto, Fabio Miraldi, Dobromir Dobrev, and Marco Zimarino
- Subjects
RBC transfusion ,Bleeding ,Transapical ,TAVI ,Mortality ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Objective: Bleeding is frequent during transcatheter aortic valve implantation (TAVI), especially when performed through a transapical approach (TA), and is associated with a worse prognosis. The present study aims to test the implication of red blood cell (RBC) transfusion and the optimal transfusion strategy in this context. Methods: Among 11,265 participants in the multicenter TRITAVI (Transfusion Requirements in Transcatheter Aortic Valve Implantation) registry, 548 patients (4.9%) who received TA-TAVI at 19 European centers were included. One-to-one propensity score matching was performed to reduce treatment selection bias and potential confounding among transfused versus non-transfused patients. The primary endpoint of the study was the 30-day occurrence of all-cause mortality. Results: 209 patients (38 %) received RBC transfusions. The primary endpoint occurred in 47 (8.6 %) patients. Propensity score matching identified 188 pairs of patients with and without RBC transfusion. In the propensity score-matched analysis, RBC transfusion was associated with increased 30-day mortality (HR 3.35, 95 % CI 1.51 – 7.39; p = 0.002). At multivariable cox regression analysis, RBC transfusion was an independent predictor of 30-day mortality (HR 3.07, 95 % CI 1.01–9.41, p = 0.048), as well as baseline ejection fraction (HR 0.96, 95 % CI 0.92–0.99, p = 0.043), and acute kidney injury (HR 3.95, 95 % CI 1.11–14.05, p = 0.034). Conclusions: RBC transfusion is an independent predictor of short-term mortality in patients undergoing TA-TAVI, regardless of major bleeding.Clinical trial registration: https://www.clinicaltrials.gov Unique identifier: NCT03740425.
- Published
- 2024
- Full Text
- View/download PDF